CHMA News and Press, Chiasma Inc. From 08/11/20

Image source: The Motley Fool. Chiasma   (NASDAQ: CHMA) Q2 2020 Earnings Call Aug 10, 2020 , 5:00 p.m. ET Operator Continue reading

Chiasma, Inc. (CHMA) Q2 2020 Results Earnings Conference Call August 10, 2020, 5:00 pm ET Company Participants Glenn Garmont - Investor Relations, Managing Director at LifeSci Advisors, LLC Raj Kannan - Director, Chief Executive Officer Bill Ludlam - Senior Vice President of Clin...

Stonebridge Biopharma plc ( SBBP ) is nearing its transformational value inflection point with the expected release of Recorlev's Phase 3 topline data for Cushing's disease due next month (September 2020). If Recorlev's Phase 3 topline data is good enough, SBBP will file a NDA in Q1 2021 with ...

Chiasma (NASDAQ: CHMA ) : Q2 GAAP EPS of -$0.50 misses by $0.13 . More news on: Chiasma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

MYCAPSSA ® U.S. commercial launch planned for the fourth quarter On track to announce MPOWERED Phase 3 trial topline data in the fourth quarter Company to host conference call today, August 10, at 5pm ET NEEDHAM, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NAS...

NEEDHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio webcast on Monday, August 10, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the ...

Chiasma (NASDAQ: CHMA ) announces 48-week data from the open-label extension (OLE) from the Phase 3 OPTIMAL trial evaluating Mycapssa (octreotide) in acromegaly patients. More news on: Chiasma, Inc., Healthcare stocks news, Stocks on the move, Read more ...

-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was maintained within normal limits at the end of the 48-week OLE period -- -- All MYCAPSS...

On Wednesday morning, Chiasma, Inc. (NASDAQ: CHMA) announced the pricing of a public offering of common stock and pre-funded warrants. Naturally, investors are not thrilled about the company's decision to dilute its existing shareholders, which explains why Chiasma's shares are plunging toda...

Chiasma sinks ( CHMA -16.3% ) after pricing  its previously announced public offering of 12.5M shares at $4/share. More news on: Chiasma, Inc., Healthcare stocks news, , Read more ...